Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

yne, PA. The mezzanine debt would have matured February 28, 2010. In addition, the facility carries an annual interest rate of 14% and would have required the issuance of a substantial number of warrants beginning June 1, 2009, if it were not terminated before that date.

"This transaction has the added benefit of reducing interest expense, fees and amortization expense by $12 million for the remainder of 2009 which greatly enhances Clarient's potential for net earnings by year end," Andrews concluded.

The purchase price of the Clarient Series A convertible preferred stock was $7.60 per share, which equates to an effective purchase price of $1.90 per share of underlying common stock or approximately market price at the date the financing was agreed upon. Under terms of the private placement, Oak may convert at any time one convertible preferred share into four shares of Clarient common stock. After one year, preferred shares, which do not accrue dividends, convert automatically into common shares if Clarient shares trade above $4.75 per share for 20 days of a 30 consecutive trading-day period. After four years, Clarient may redeem any unconverted preferred shares at $7.60 per share plus any undeclared but unpaid dividends.

Upon mutual agreement after the closing of the second tranche, Oak may purchase up to an additional $10 million of Clarient preferred shares, providing the company access to capital for strategic opportunities that would accelerate the company's growth.

The private placement gives Oak effective control of approximately 21% of Clarient's outstanding shares and reduces Safeguard's position to approximately 47% from nearly 62% at December 31, 2008. With certain exceptions, preferred shares will be voted with common shares on an as-converted basis. Safeguard first took an ownership stake in Clarient in 1996, increasing its position over time.

About Clarient
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink ... term. They are the first functional focus beverage to ... an alternative to the temporary fix associated with energy ... July 29, 2014, with hopes to raise $50,000 over ... - http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks ...
(Date:7/23/2014)... year, Formedix celebrated its partnership with ... management solutions for clinical trials. The company launched its ... capture (EDC) and clinical data management. Formedix, a renowned ... TrialMaster to its Transform for EDC product line. This ... is being released this week, in response to market ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 StemGenex® ... therapy in the US aimed at improving the lives ... newest clinical study for Parkinson’s disease. StemGenex believes ... stem cell therapy are paramount when providing care to ... study makes stem cell therapy accessible to the millions ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3
... BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, ... Roche Company, and SoftGenetics announced today that the ... designed to provide users of 454 Sequencing Systems ... options provided by SoftGenetics NextGENe® software. ...
... JERICHO, N.Y., May 8, 2012 Health Care ... response to continued recent devastating natural and man-made ... the HCCS online training course, "Bioterrorism and Disaster ... (Logo:  http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ) "HCCS ...
... COPENHAGEN, May 8, 2012  Ekahau ... Location Systems (RTLS), today announced the launch of its newest ... Pager .  The B4 features an OLED text display and multiple ... to acknowledge receipt or to initiate calls and alarms. A unique ...
Cached Biology Technology:Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 2Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 3Free Disaster Preparedness Online Training Course 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 3
(Date:7/23/2014)... This news release is available in German . ... shape and stability to cells, drive metabolic processes and ... into complex three-dimensional shapes. Scientists at the Max Planck ... that proteins can be constructed of similar amino acid ... suggests that the proteins that exist today arose from ...
(Date:7/23/2014)... Innovative Networking in personalized cancer medicine, (the WIN consortium), ... Thomas Jefferson University will be one of ... this prestigious group in the Tri-State Area. The goal ... personalized medicine to the patient by forging collaborations between ... participation in the WIN consortium means Jefferson cancer patients ...
(Date:7/23/2014)... As local and national governments struggle to deal with ... now refining the picture of just how much there ... the ACS journal Environmental Science & Technology , ... that developed countries discard floods into just seven developing ... people who live there. , Knut Breivik and colleagues ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2New partnership brings more personalized cancer treatment to Philadelphia 2
... 2011) -- In a biotechnological tour de force, Rice ... for rapidly converting simple glucose into biofuels and petrochemical ... , Rice,s team described how it reversed one of ... beta oxidation cycle -- to engineer bacteria that produce ...
... Cambridge, Mass. - August 10, 2011 - Between conception ... meters long, looping and coiling within the tiny abdomen. ... loops into the same formationhowever, until now, it has ... experimental observations, biological and biophysical manipulations, theory, and computation, ...
... Genetically engineered spider silk could help overcome a major ... according to a new study that reported development and successful ... ACS, journal Bioconjugate Chemistry . David Kaplan and ... genes to prevent or treat disease requires safe and ...
Cached Biology News:Metabolism in reverse: Making biofuels at full-throttle pace 2Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
UBC13 Antibody...
... SAPK/JNK (Thr183/Tyr185) Antibody Kit Kit ... Catalog #9251, 200 ul SAPK/JNK (56G8) ... SAPK/JNK Cell Extracts, Catalog #9253, (4 ... Catalog #7074, 100 ul Anti-biotin IgG, ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: